Cited 9 times in
Tetraspanin CD151 expression associated with prognosis for patients with advanced gastric cancer.
|dc.description.abstract||PURPOSE: Tetraspanin CD151 is known to be involved in cancer invasion and metastasis, and its overexpression appears to be associated with a poor prognosis for various types of cancer. However, the expression status of CD151 and its prognostic impact in advanced gastric cancer (AGC) has not yet been clarified.|
METHODS: Immunohistochemistry was used to investigate the expression of CD151, c-erbB2, and c-Met in 159 cases of AGC. The clinicopathological and prognostic significance of these biomarkers were then evaluated.
RESULTS: The overexpression of CD151 was observed in a subset of advanced gastric adenocarcinomas (25.8 %), and c-erbB2 and c-Met were overexpressed in 15.1 and 35.2 % of the cohort, respectively. CD151 overexpression was more frequently observed in tumors from younger patients (P = 0.028). There were close associations between CD151 and c-erbB2 overexpression (P = 0.033) and between c-erbB2 and c-Met overexpression (P = 0.001). CD151 overexpression was closely correlated with patient' overall survival (OS; P < 0.001) and disease-free survival (DFS; P < 0.001). Furthermore, the expression rate of CD151 seemed to increase gradually according to the depth of invasion (T stage) (χ(2) test for trend; P = 0.101), N stage (P = 0.238), and pathologic stage (P = 0.153), although trends were not statistically significant. In a multivariate analysis, CD151 overexpression was an independent prognostic factor predicting worse OS (P = 0.002) and DFS (P = 0.005), along with the T and N stage.
CONCLUSIONS: CD151 was found to be an independent prognostic marker for patients with AGC.
|dc.subject.MESH||Aged, 80 and over||-|
|dc.subject.MESH||Antineoplastic Combined Chemotherapy Protocols/therapeutic use||-|
|dc.subject.MESH||Cisplatin/administration & dosage||-|
|dc.subject.MESH||Digestive System Surgical Procedures||-|
|dc.subject.MESH||Lymph Node Excision||-|
|dc.subject.MESH||Oxonic Acid/administration & dosage||-|
|dc.subject.MESH||Receptor Protein-Tyrosine Kinases/biosynthesis||-|
|dc.subject.MESH||Tegafur/administration & dosage||-|
|dc.subject.MESH||Tumor Markers, Biological/biosynthesis||-|
|dc.title||Tetraspanin CD151 expression associated with prognosis for patients with advanced gastric cancer.||-|
|dc.citation.title||Journal of cancer research and clinical oncology||-|
|dc.identifier.bibliographicCitation||Journal of cancer research and clinical oncology, 139(11):1835-1843, 2013||-|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.